My ePortfolio Register   

Bridging tumour moats with potent drug delivery particles

Despite herculean efforts, cancer remains a formidable disease, with each malignant subtype responding differently to therapeutics.

One hurdle specific to treating solid tumours is a protective layer called an extracellular matrix that can prevent chemotherapeutic agents from penetrating the tumour's core.

Scientists now report results in ACS' Chemistry of Materials showing that, by cloaking anti-cancer drugs in a specially designed particle, they could target and destroy tumour cells deep inside a malignant mass in vitro.

For tumours that can't be extracted with surgery, radiation and chemotherapy are the treatments of choice, but both can involve serious side effects due to a lack of specificity: They'll kill healthy cells along with malignant ones.

Researchers have long known that, thanks to the unique blood vessel architecture surrounding tumours, nanoparticles can easily pass into the cancer zone, offering a potential route for the specific delivery of chemotherapies to cancer cells.

However, efforts to exploit this phenomenon have fallen short, with experimental drug-loaded particles failing because they can't get through the dense extracellular matrix or they lose the therapeutic payload en route to the tumour's interior.

Alejandro Baeza, C. Jeffrey Brinker, Maria Vallet-Regi and colleagues addressed this shortcoming by developing a brand-new type of particle.

The researchers created a "protocell," a nanoparticle that can carve through the extracellular matrix, delivering cell-killing doses of drug to the deepest tumour regions.

To develop the protocell, the team started with a mesoporous silica skeleton with a high internal surface area that can contain a large amount of drug.

They surrounded this skeleton with a lipid bilayer outfitted with an array of tools to help the protocell deliver its drug arsenal to the desired locale, including enzymes that cleave collagen, a major component of the tumour's extracellular matrix.

The protocell also features pH-sensitive ligands that trigger the release of the drug upon entry into the relatively acidic interior of a cell, ensuring the medication is only delivered where needed.

The researchers tested the protocells in a 3-D cell culture model of a solid tumour, showing that the protocell penetrates and destroys malignant cells better than drug-loaded protocells without the enhanced toolkit potential to one day treat cancer and other diseases in the female reproductive tract.

Source: American Chemical Society

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence